GUARNERI, PATRIZIA
 Distribuzione geografica
Continente #
NA - Nord America 727
AS - Asia 271
EU - Europa 250
SA - Sud America 3
AF - Africa 1
Totale 1.252
Nazione #
US - Stati Uniti d'America 726
SG - Singapore 249
IT - Italia 194
NL - Olanda 20
FI - Finlandia 16
JP - Giappone 11
DE - Germania 8
CN - Cina 3
FR - Francia 3
LV - Lettonia 3
AT - Austria 2
KR - Corea 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BD - Bangladesh 1
BR - Brasile 1
CH - Svizzera 1
GB - Regno Unito 1
HK - Hong Kong 1
ID - Indonesia 1
IS - Islanda 1
JO - Giordania 1
MA - Marocco 1
PA - Panama 1
PE - Perù 1
SE - Svezia 1
VN - Vietnam 1
Totale 1.252
Città #
Santa Clara 652
Singapore 171
Milan 19
Helsinki 16
Rome 16
Bitonto 11
Minamimotomachi 11
Naples 11
Turin 10
Florence 9
Reggio Calabria 9
Palermo 8
Ashburn 5
Los Angeles 5
Barcellona Pozzo di Gotto 3
Bologna 3
Cavallino 3
Messina 3
Riga 3
Vicenza 3
Brescia 2
Castelli Calepio 2
Latina 2
Lissone 2
Nuremberg 2
Parma 2
Phoenix 2
Pinerolo 2
Seoul 2
Vienna 2
West Jordan 2
Amman 1
Buenos Aires 1
Caltanissetta 1
Casale Monferrato 1
Catania 1
Dhaka 1
Dubai 1
Guangzhou 1
Hong Kong 1
Lima 1
Marano di Napoli 1
Modesto 1
Monza 1
Perugia 1
Piubega 1
Reykjavik 1
Roverbella 1
São Paulo 1
Zurich 1
Totale 1.012
Nome #
Analisi farmacologiche di nuovi sistemi nanoparticellari per il rilascio del blu di metilene con potenziali effetti nelle malattie neurodegenerative 123
Variazioni dell'espressione di VAPB e dei suoi prodotti di clivaggio nei pazienti con Sclerosi Laterale Amiotrofica 27
Eye drops of Ch-Cx carrier silibinin inducing protection in a model of Age-related Macular Disease (AMD). 25
Neuroanatomia - Un approccio semplice e comprensibile 19
Expression of VAPB cleavage of products in peripheral blood leukocytes and cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis 19
Nanospheres based on PLGA/amphiphilic cyclodextrin assemblies as potential enhancers of Methylene Blue neuroprotective effect 17
CRISPR/Cas9 "CLN8 null" towards a dysfunctional autophagy in CLN8-associated neuronal ceroid lipofuscinosis diseases-ePoster # 4774 16
NANOSTRUCTURED FORMULATIONS FOR THE DELIVERY OF SILIBININ AND OTHER ACTIVE INGREDIENTS FOR TREATING OCULAR DISEASES 16
A potential interactome map of CLN8 protein involved in the late-infantile form of neuronal ceroid lipofuscinosis. 14
La patogenesi delle varianti CLN8 nelle ceroidolipofuscinosi. 14
A bicistronic vector to study the effect of CLN8/VAPA interaction on cell physiology and eventually the pathology of CLN8-associated NLC diseases 13
Low concentrations of silibinin and choline-calixarene or INU-C8-PEG carriers assembling silibinin promote antioxidant and antiapoptotic effects in neuronal and retinal epithelial cells. 13
The estrogenic retina: The potential contribution to healthy aging and age-related neurodegenerative diseases of the retina 13
Estrogen receptors in HAECs: neuronal differentiation and stemness. 13
Targeting lipids in CLN8-associated NCL diseases: structural and functional interaction of CLN8 with vesicle-associated membrane protein-associated protein A (VAPA), and genotype-phenotype correlations. II Report 13
CLN8 protein: a post-translation modification and subcellular distribution study for understanding CLN8 physiopathology 13
Formulations used to treat ocular diseases comprising e.g. macular edema, uveitis, comprise active ingredients incorporated in nanostructured systems 12
Autophagy and mitophagy in the CLN8mnd mouse, a model of childhood neurodegenerative diseases 12
Targeting lipids in CLN8-associated NCL diseases: structural and functional interaction of CLN8 with vesicle-associated membrane protein-associated protein A (VAPA), and genotype-phenotype correlations. TELETHON Grant GGP16277 12
Neurosteroids in the retina: neurodegenerative and neuroprotective agents in retinal degeneration 12
Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases 12
Interaction of alphaA-crystallin with beta-amyloid in diabetic retina: an emerging antifibrillogenesis activity. 12
The role of autophagy in the CLN8mnd mouse model of neuronal ceroid lipofuscinosis. 12
Topical application of choline-calix[4]arene nanocarrier of silibinin reduces retinal damage in a model of Age-Related Macular Disease. 12
Targeting lipids in CLN8-associated NCL diseases: structural and functional interaction of CLN8 with Vesicle-Associated Membrane Protein-associated Protein A (VAPA), and genotype-phenotype correlations 12
Progetto Invecchiamento "PNR-CNR Aging Program 2012-2014 PI.P02 "Invecchiamento: Innovazioni tecnologiche e molecolari per un miglioramento della salute dell'anziano" 12
TNF-alpha and TNF receptor 1 in retinal and optic nerve degeneration of the CLN8 mutant mouse. 11
Modelli retinici per le nanotecnologie e il biomonitoraggio ambientale 11
17b-estradiol synthesis in the adult male rat retina. 11
HIPPOCRATES PON02_00355 Regione Sicilia - Sviluppo di Micro e Nano-Tecnologie e Sistemi Avanzati per la Salute dell'uomo. 11
Tackling mechanisms of CLN8 mutations in neuronal ceroid lipofuscinosis (NCLs). 11
Identifying protein partners of CLN8, an ER-resident protein involved in neuronal ceroid lipofuscinosis 11
Effetti di nuove diketopiperazine in un modello in vivo di Degenerazione Maculare Senile 11
Sustained release of silibinin to the posterior segment of the eye by mucoadhesive NLC 11
Iron accumulation and retinal pathology: neuroprotection by diketopiperazines 11
Riunione Annuale CLNet 11
Different early ER-stress responses in the CLN8mnd mouse model of neuronal ceroid lipofuscinosis. 10
Neglected CLN8 protein function in the neuronal ceroid lipofuscinoses (NCLs). 10
A role of estrogens in the retina. 10
Identification of an antigen related to the sea urchin RNA-binding protein LP54 in mammalian central nervous system. 10
Orphanet - Il portale delle malattie rare e dei farmaci orfani: The CLN8 variant late-infantile neuronal ceroid lipofuscinosis (CLN8-vLINCL): functional aspects of the CLN8 protein and characterization of the degenerative mechanisms . 10
VAPB as a possible disease-modifier of ALS. 10
Sistemi modello di patologie retiniche e neurodegenerative e strategie per la comprensione, la diagnosi e la terapia. 10
Neurosteroidogenic pathways toward retinal neurodegeneration and neuroprotection 9
The neurosteroid pregnenolone sulfate contributes to neuronal cell death 9
TRAIL and TRAIL neutralizing antibody in the retina and RPE/choroid of the 3xTg-AD mouse model of Alzheimer disease. 9
Orphanet - Il portale delle malattie rare e dei farmaci orfani: Biological and genetic variables in the pathogenesis and clinical progression of amyotrophic lateral sclerosis: identification of biomarkers . 9
Retinal oxidation, apoptosis and age- and sex-differences in the mnd mutant mouse, a model of neuronal ceroid lipofuscinosis 9
Mediatori aminoacidici della retina 8
Pregnenolone sulfate modulates NMDA receptors, inducing and potentiating acute excitotoxicity in isolated retina 8
NEUROSTEROIDOGENESIS IN RAT RETINAS 8
The protective role of Estrogen-Receptor-Beta in retinal excitotoxicity. 8
Estrogen and androgen regulation of the small heat shock protein ±A-crystallin: New perspectives on sex steroid implication in age-related disorders associated with proteotoxic stress. 8
Mitochondrial oxidative metabolism in motor neuron degeneration (mnd) mouse central nervous system 8
Execution pathways of pregnenolone sulfate-induced retinal apoptosis 8
CAMP/PKA-linked phosphorylation and cytoskeletal organization are required for cholesterol transport and neurosteroid synthesis in neuroblastoma SH-SY5Y cells 8
High vulnerability of estrogen-producing retinal cells to excitotoxic insult: downregulation of P450 aromatase activity 8
GAMMA-AMINOBUTYRIC-ACID TYPE-A BENZODIAZEPINE RECEPTORS REGULATE RAT RETINA NEUROSTEROIDOGENESIS 8
Disfunzione autofagica precoce nella malattia da accumulo lisosomiale tipo ceroidolipofuscinosi associata al gene CLN8 8
Uridina e complesso recettoriale GABA Benzodiazepine ionoforo. 8
Retinal oxidation and apoptosis in the motor neuron degeneration mouse, a model of neuronal ceroid lipofuscinosis 8
Studi di biodisponibilità della Silibinina strutturata in nanoparticelle per la terapia di patologie retiniche neurodegenerative 8
TNF-alpha and TNF receptor 1 in retinal and optic nerve degeneration of the CLN8 mutant mouse 8
INVOLVEMENT OF p38 AND JNK mapks PATHWAYS IN SUBSTANCE P-INDUCED PRODUCTION OF TNF - BY PERITONEAL MAST CELLS 8
Induction of neurosteroid synthesis by NMDA receptors in isolated rat retina: a potential early event in excitotoxicity 8
Neurosteroidogenic pathways toward retina neurodegeneration or neuroprotection 8
An early impact of ER stress, inflammation and oxidative stress in the CLN8mnd mouse model of neuronal ceroid lipofuscinosis 8
CLN8 interactors: a possible function of the CLN8 protein in the lipid metabolism and autophagy 8
Lateralization of GABA receptors in the rat brain. 8
DBI (DIAZEPAM BINDING INHIBITOR) - THE PRECURSOR OF A FAMILY OF ENDOGENOUS MODULATORS OF GABA-A RECEPTOR FUNCTION - HISTORY, PERSPECTIVES, AND CLINICAL IMPLICATIONS 7
Facts News & Views Organo Ufficiale della Società Italiana di NeuroPsicoFarmacologia. Numero Speciale 7
Effect of uridine of GABA receptors. 7
Does neurosteroidogenesis contribute to neuronal excitotoxicity? 7
CNR Environment and Health Inter-departmental Project: present knowledge and prospects for future research. 7
TRITIATED L LYSINE BINDING TO RAT RETINAL MEMBRANE II. EFFECT OF KAINIC ACID D L-ALPHA AMINOADIPIC ACID IODOACETIC ACID AND MODIFICATION BY DARK-EXPOSURE 7
Human neuroblastoma SH-SY5Y cell line: Neurosteroid-producing cell line relying on cytoskeletal organization 7
INTERACTION OF URIDINE WITH GAMMA AMINO BUTYRIC-ACID BINDING SITES IN CEREBELLAR MEMBRANES OF THE RAT 7
Ricerca Sanitaria 2007 "Identification of biological, genetic and clinical modifiers of the rate of progression and survival in amyotrophic lateral sclerosis" 7
Functional analysis of L-3H Iysine binding to the rat retina. 7
"ZEISS on Your Campus" 7
Neurosteroids in the retina: neurodegenerative and neuroprotective agents in retinal degeneration. 7
A caspase-3-dependent pathway is predominantly activated by the excitotoxin pregnenolone sulfate and requires early and late cytochrome c release and cell-speci.c caspase-2 activation in the retinal cell death 7
Ruolo degli estrogeni nella neuroprotezione della retina 7
ENDOPLASMIC RETICULUM STRESS AND THE UNFOLDED PROTEIN RESPONSE IN THE Cln8mnd MOUSE MODEL OF NEURONAL CEROID LIPOFUSCINOSES (NCLS) 7
High vulnerability of estrogen-producing retinal cells to excitotoxic insult: downregulation of P450 aromatase activity 7
STRUCTURE SPECIFICITY OF ER STRESS IN THE CLN-MND MOUSE MODEL OF THE LATE-INFANTILE NEURONAL CEROID LIPOFUSCINOSIS 7
LDH, MDH, ATPasi nel sistema nervoso periferico di ratti sottoposti ad iperglicemia sperimentale. 7
AGE RELATED CHANGES OF BENZODIAZEPINE AND GAMMA AMINO BUTYRIC-ACID BINDING SITES IN THE RAT RETINA 7
GABA and benzodiazepine receptors in the rat retina: loss of their functional interaction with age. 7
Peripheral-type benzodiazepine receptor role in the regulation of steroid and neurosteroid biosynthesis 7
Pregnenolone sulfate, a naturally occurring excitotoxin involved in delayed retinal cell death 7
Studies of endogenous modulator of GABAA, receptors in human brain and CSF. 7
Lavoriamo per curare le malattie neurodegenerative dell'infanzia. 7
Il Professore: Ricordi di Erminio Costa 7
Steroid synthesis by glial cells 7
Retinal steroidogenic machinery: expression and activity of P450scc, P450c17, 3bHSD, P450aromatase 7
CLN8 and VAP-A, a possible protein-protein interaction at the ER for the regulation of lipid metabolism and with implication in neurodegenerative diseases. 7
Neurosteroid synthesis: an early event in retinal neurodegeneration 6
PATHOGENIC MECHANISMS IN THE CLN8 FORM OF THE LATE-INFANTILE NEURONAL CEROID LIPOFUSCINOSIS. NEW INSIGHTS INTO THE VISUAL LOSS FROM THE CLN8mnd MOUSE MODEL 6
The protective role of estrogen-receptor-beta in retinal excitotoxicity. 6
Totale 1.095
Categoria #
all - tutte 5.248
article - articoli 1.786
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 307
Totale 7.341


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202431 0 0 0 0 0 0 0 0 17 3 5 6
2024/20251.221 14 9 162 120 635 62 29 71 119 0 0 0
Totale 1.252